PL354399A1 - Farmaceutyczne postacie dawkowane o kontrolowanymuwalnianiu z co najmniej impulsem czasowym - Google Patents

Farmaceutyczne postacie dawkowane o kontrolowanymuwalnianiu z co najmniej impulsem czasowym

Info

Publication number
PL354399A1
PL354399A1 PL00354399A PL35439900A PL354399A1 PL 354399 A1 PL354399 A1 PL 354399A1 PL 00354399 A PL00354399 A PL 00354399A PL 35439900 A PL35439900 A PL 35439900A PL 354399 A1 PL354399 A1 PL 354399A1
Authority
PL
Poland
Prior art keywords
dosage forms
controlled release
pharmaceutical dosage
timed pulse
release producing
Prior art date
Application number
PL00354399A
Other languages
English (en)
Other versions
PL200816B1 (pl
Inventor
Frederic Andre
Gareth Lewis
Jerome Mignonneau
Agnes Ribardiere
Original Assignee
Sanofi-Synthelabo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi-Synthelabo filed Critical Sanofi-Synthelabo
Publication of PL354399A1 publication Critical patent/PL354399A1/pl
Publication of PL200816B1 publication Critical patent/PL200816B1/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5015—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PL354399A 1999-06-28 2000-06-27 Powleczony rdzeń o opóźnionym uwalnianiu dający impuls czasowy uwalniania i farmaceutyczna postać dawkowana PL200816B1 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP99401606A EP1064938A1 (en) 1999-06-28 1999-06-28 Pharmaceutical dosage forms for controlled release producing at least a timed pulse
PCT/EP2000/006795 WO2001000182A1 (en) 1999-06-28 2000-06-27 Pharmaceutical dosage forms for controlled release producing at least a timed pulse

Publications (2)

Publication Number Publication Date
PL354399A1 true PL354399A1 (pl) 2004-01-12
PL200816B1 PL200816B1 (pl) 2009-02-27

Family

ID=8242029

Family Applications (1)

Application Number Title Priority Date Filing Date
PL354399A PL200816B1 (pl) 1999-06-28 2000-06-27 Powleczony rdzeń o opóźnionym uwalnianiu dający impuls czasowy uwalniania i farmaceutyczna postać dawkowana

Country Status (29)

Country Link
US (1) US20080175910A1 (pl)
EP (2) EP1064938A1 (pl)
JP (1) JP2003503341A (pl)
KR (1) KR100794402B1 (pl)
CN (2) CN1358088A (pl)
AR (1) AR024492A1 (pl)
AT (1) ATE274902T1 (pl)
AU (1) AU780769B2 (pl)
BR (1) BR0011999A (pl)
CA (1) CA2370067C (pl)
CO (1) CO5190681A1 (pl)
CZ (1) CZ296067B6 (pl)
DE (1) DE60013445T2 (pl)
DK (1) DK1194131T3 (pl)
ES (1) ES2225183T3 (pl)
HK (1) HK1043056B (pl)
HU (1) HU229312B1 (pl)
IL (2) IL146768A0 (pl)
MX (1) MXPA01013408A (pl)
NO (1) NO332952B1 (pl)
NZ (1) NZ515826A (pl)
PL (1) PL200816B1 (pl)
PT (1) PT1194131E (pl)
SI (1) SI1194131T1 (pl)
SK (1) SK285359B6 (pl)
TR (1) TR200103604T2 (pl)
TW (1) TWI242451B (pl)
WO (1) WO2001000182A1 (pl)
ZA (1) ZA200109849B (pl)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AP1748A (en) 2001-03-13 2007-06-11 Penwest Pharmaceuticals Co Chronotherapeutic dosage forms.
DE10149674A1 (de) 2001-10-09 2003-04-24 Apogepha Arzneimittel Gmbh Orale Darreichungsformen für Propiverin oder seinen pharmazeutisch annehmbaren Salzen mit verlängerter Wirkstoffreisetzung
JP2005512997A (ja) * 2001-11-07 2005-05-12 シントン・ベスローテン・フェンノートシャップ タムスロシン錠
WO2003045437A1 (en) * 2001-11-30 2003-06-05 Pfizer Products Inc. Pharmaceutical compositions of 5,7,14-triazatetracyclo[10.3.1.0(2,11).0(4,9)]-hexadeca-2(11)3,5,7,9-pentaene
CN1606434A (zh) * 2001-12-19 2005-04-13 株式会社三和化学研究所 控制释放成型品
MXPA05000128A (es) * 2002-07-05 2005-09-30 Temrel Inc Composicion de liberacion controlada.
MY148805A (en) 2002-10-16 2013-05-31 Takeda Pharmaceutical Controlled release preparation
CN1720026A (zh) * 2002-10-22 2006-01-11 兰贝克赛实验室有限公司 含有阿夫唑嗪的缓释组合物
US7018658B2 (en) * 2002-11-14 2006-03-28 Synthon Bv Pharmaceutical pellets comprising tamsulosin
KR100592512B1 (ko) * 2002-11-22 2006-07-03 서울약품공업(주) 탐술로신 또는 약제학적으로 허용되는 이의 염을활성성분으로 하는 서방성 배뇨장애 치료제
IN192381B (pl) * 2002-12-20 2004-04-10 Ranbaxy Lab
MXPA06003101A (es) * 2003-09-19 2006-06-20 Penwest Pharmaceuticals Co Formas de dosis cronoterapeuticas.
US8389008B2 (en) * 2003-09-19 2013-03-05 Penwest Pharmaceuticals Co. Delayed release dosage forms
GB2407498B (en) * 2003-10-30 2008-06-11 Cipla Ltd Oral formulations for 5-HT receptor agonists with reduced degradation of active ingredient
KR100436701B1 (ko) * 2003-11-07 2004-06-22 주식회사 씨티씨바이오 염산 탐스로신 함유 방출 조절형 제제 및 그의 제조방법
US8292729B2 (en) 2003-12-02 2012-10-23 United Tote Company Methods and systems for presenting pari-mutuel betting options and constructing wagers
GB2411355B (en) 2004-02-27 2006-02-22 Niche Generics Ltd Pharmaceutical composition
AR051654A1 (es) * 2004-11-04 2007-01-31 Astrazeneca Ab Nuevas formulaciones de pellets de liberacion modificada para inhibidores de la bomba de protones
AR052225A1 (es) * 2004-11-04 2007-03-07 Astrazeneca Ab Formulaciones de tabletas de liberacion modificada par inhibidores de la bomba de protones
WO2006055659A2 (en) * 2004-11-15 2006-05-26 Smithkline Beecham Corporation Fixed dose combination op dutasteride and tamsulosin
CN101132777A (zh) * 2004-12-20 2008-02-27 科利吉姆制药公司 用于睡眠障碍的药物组合物
BRPI0606932A2 (pt) * 2005-01-26 2009-07-28 Elan Pharma Int Ltd formulação, forma de dosagem, e, uso de uma quantidade terapeuticamente efetiva de uma formulação
WO2006102965A1 (en) * 2005-03-29 2006-10-05 Evonik Röhm Gmbh Multiparticulate pharmaceutical form comprising pellets with a matrix which influences the delivery of a modulatory substance
EP1976488A4 (en) 2006-01-12 2010-02-10 Wockhardt Ltd ALFUZOSIN PROLONGED RELEASE PREPARATIONS
US20070292505A1 (en) * 2006-06-15 2007-12-20 Abrika Pharmaceuticals, Inc. Controlled release alfuzosin hydrochloride formulation
US20080095844A1 (en) * 2006-10-23 2008-04-24 Rajhans Sujay Kamalakar Sustained release pharmaceutical compositions of alfuzosin and process for preparation thereof
CN101269056B (zh) * 2007-03-19 2010-05-19 天津药物研究院 一种美托洛尔盐类口服脉冲微丸制剂
US8178483B2 (en) * 2007-03-30 2012-05-15 Colgate-Palmolive Company Polymeric encapsulates having a quaternary ammonium salt and methods for producing the same
JP5228359B2 (ja) * 2007-04-12 2013-07-03 ニプロ株式会社 主薬粒子及びその製造方法ならびに口腔内崩壊錠
FR2928929B1 (fr) * 2008-03-19 2012-01-13 Saint Gobain Composition serigraphiable sur polyvinylbutyral
KR101573889B1 (ko) 2009-10-09 2015-12-04 영진약품공업주식회사 속효성과 지속성을 동시에 갖는 약제학적 조성물
CN102106841B (zh) * 2009-12-24 2013-01-09 杭州康恩贝制药有限公司 一种盐酸坦洛新制剂及其制备方法
NZ706991A (en) 2010-03-29 2016-08-26 Ferring Bv A fast dissolving pharmaceutical composition
JO3112B1 (ar) 2010-03-29 2017-09-20 Ferring Bv تركيبة دوائية سريعة التحلل
KR101686033B1 (ko) * 2010-04-12 2016-12-13 주식회사 대웅제약 탐술로신 또는 이의 약제학적 허용 가능한 염을 유효성분으로 함유하는 장용성 서방형 펠렛부와 속방부로 이루어진 의약 조성물
WO2011144994A1 (en) * 2010-05-21 2011-11-24 Lupin Limited Pharmaceutical compositions of nsaid and acid inhibitor
US8623409B1 (en) 2010-10-20 2014-01-07 Tris Pharma Inc. Clonidine formulation
TW201422254A (zh) * 2012-11-21 2014-06-16 Ferring Bv 用於速釋及延釋的組成物
CA3001065A1 (en) 2015-10-14 2017-04-20 Xiaoxi WEI Compositions and methods for reducing ice crystal formation
CN105362233A (zh) * 2015-12-07 2016-03-02 黑龙江省智诚医药科技有限公司 一种卡托普利缓释微丸及其制备方法
SG11201903829PA (en) * 2016-10-31 2019-05-30 Neurim Pharma 1991 Melatonin mini-tablets and method of manufacturing the same
US10849856B2 (en) 2016-10-31 2020-12-01 Neurim Pharmaceuticals Ltd. Melatonin mini-tablets and method of manufacturing the same
US10278930B2 (en) 2017-03-16 2019-05-07 The Procter & Gamble Company Method for relieving sinus congestion
CN107233328A (zh) * 2017-06-13 2017-10-10 江苏黄河药业股份有限公司 卡托普利缓释片剂及其制备方法
CN107362161B (zh) * 2017-08-14 2020-05-29 黄河科技学院 一种复方卡托普利硝苯地平脉冲缓释制剂及其制备方法
TR201721036A2 (tr) * 2017-12-21 2019-07-22 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Flurbi̇profeni̇n modi̇fi̇ye salimli formülasyonlari
JP7162330B2 (ja) * 2018-07-11 2022-10-28 株式会社アタゴ 粘度計
CN110075090A (zh) * 2019-05-17 2019-08-02 南京望知星医药科技有限公司 一种用于治疗呼吸疾病的沙丁胺醇胶囊及其制备方法
CN110037994B (zh) * 2019-05-24 2022-04-12 中国药科大学 一种布洛芬速释缓释双层片及其制备方法
US11918689B1 (en) 2020-07-28 2024-03-05 Tris Pharma Inc Liquid clonidine extended release composition

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA822995B (en) * 1981-05-21 1983-12-28 Wyeth John & Brother Ltd Slow release pharmaceutical composition
US4677099A (en) * 1981-09-04 1987-06-30 Yeda Research And Development Co., Ltd. Medical processes employing a novel lipid fraction
US4370313A (en) * 1981-10-26 1983-01-25 Eaton Laboratories, Inc. Nitrofurantoin dosage form
JPS58116414A (ja) * 1981-12-23 1983-07-11 Yamanouchi Pharmaceut Co Ltd ニカルジピン持続性製剤用球形顆粒およびその製造法
US4614796A (en) * 1983-03-25 1986-09-30 Nippon Shinyaku Co., Ltd. Liposome and method of manufacture therefor
EP0212746B1 (en) * 1985-08-16 1991-04-10 The Procter & Gamble Company Drug particles having constant release
US4986987A (en) * 1986-05-09 1991-01-22 Alza Corporation Pulsed drug delivery
US4994273A (en) * 1987-11-02 1991-02-19 Merck & Co., Inc. Solubility modulated drug delivery device
ATE124864T1 (de) * 1989-03-10 1995-07-15 Yamanouchi Pharma Co Ltd Die wirkstoffabgabe steuerndes überzugsmaterial für lang wirksame formulierungen.
US5176901A (en) * 1991-04-10 1993-01-05 Smithkline Beecham Corporation Dental composition
ES2106818T3 (es) * 1991-10-30 1997-11-16 Glaxo Group Ltd Composicion multicapa que contiene antagonistas de histamina o secotina.
HU227530B1 (en) * 1991-11-22 2011-07-28 Warner Chilcott Company Delayed-release compositions containing risedronate and process for their production
US5472711A (en) * 1992-07-30 1995-12-05 Edward Mendell Co., Inc. Agglomerated hydrophilic complexes with multi-phasic release characteristics
JP2949448B2 (ja) * 1992-11-30 1999-09-13 ケーヴィ ファーマセチカル カンパニー 味を隠された医薬材料
JPH09500645A (ja) * 1993-07-22 1997-01-21 ワーナー−ランバート・コンパニー 制御放出タクリン薬物送達システムおよびその製造方法
FR2717388B1 (fr) * 1994-03-21 1996-11-22 Synthelabo Formes galéniques à libération prolongée du chlorhydrate d'alfuzosine.
US5834024A (en) * 1995-01-05 1998-11-10 Fh Faulding & Co. Limited Controlled absorption diltiazem pharmaceutical formulation
US5948438A (en) * 1995-01-09 1999-09-07 Edward Mendell Co., Inc. Pharmaceutical formulations having improved disintegration and/or absorptivity
IL116674A (en) * 1995-01-09 2003-05-29 Mendell Co Inc Edward Microcrystalline cellulose-based excipient having improved compressibility, pharmaceutical compositions containing the same and methods for the preparation of said excipient and of solid dosage form thereof
US5585115A (en) * 1995-01-09 1996-12-17 Edward H. Mendell Co., Inc. Pharmaceutical excipient having improved compressability
IE80467B1 (en) * 1995-07-03 1998-07-29 Elan Corp Plc Controlled release formulations for poorly soluble drugs
FR2742660B1 (fr) * 1995-12-22 1998-04-03 Ethypharm Lab Prod Ethiques Nouvelles formes de microgranules a liberation prolongee contenant du diltiazem comme principe actif
US5840332A (en) * 1996-01-18 1998-11-24 Perio Products Ltd. Gastrointestinal drug delivery system
AUPN969796A0 (en) * 1996-05-07 1996-05-30 F.H. Faulding & Co. Limited Taste masked liquid suspensions
DE19637082A1 (de) * 1996-09-12 1998-03-19 Boehringer Mannheim Gmbh Schnellzerfallende Pellets
US6020375A (en) * 1997-06-13 2000-02-01 Senju Pharmaceutical Co., Ltd. Bactericidal composition
BR9802915A (pt) * 1997-09-12 2000-01-11 Oscar Gold Procedimento para formar composições farmaceuticas em pilulas ou granulos substancialmente esfericos, de ação controlada e continuada, contendo como agente ativo o (7-bromo-1,3-diidro-5-(2-piridninilo)-2h-1,4-benzodiazep ina-2(1h)-um)
US6066339A (en) * 1997-10-17 2000-05-23 Elan Corporation, Plc Oral morphine multiparticulate formulation
US5922341A (en) * 1997-10-28 1999-07-13 Vivus, Incorporated Local administration of pharmacologically active agents to treat premature ejaculation
DK173431B1 (da) * 1998-03-20 2000-10-23 Gea Farmaceutisk Fabrik As Farmaceutisk formulering omfattende en 2-[[(2-pyridinyl)methyl]sulfinyl]benzimidazol med anti-ulcusaktivitet samt fremgangs
US6124362A (en) * 1998-07-17 2000-09-26 The Procter & Gamble Company Method for regulating hair growth
US6270805B1 (en) * 1998-11-06 2001-08-07 Andrx Pharmaceuticals, Inc. Two pellet controlled release formulation for water soluble drugs which contains an alkaline metal stearate
US7374779B2 (en) * 1999-02-26 2008-05-20 Lipocine, Inc. Pharmaceutical formulations and systems for improved absorption and multistage release of active agents
US6495498B2 (en) * 1999-05-27 2002-12-17 Johnson & Johnson Consumer Companies, Inc. Detergent compositions with enhanced depositing, conditioning and softness capabilities
EP1064937A1 (en) * 1999-06-28 2001-01-03 Sanofi-Synthelabo Timed dual release dosage forms comprising a short acting hypnotic or a salt thereof

Also Published As

Publication number Publication date
NO20016282D0 (no) 2001-12-20
CN101669914A (zh) 2010-03-17
TWI242451B (en) 2005-11-01
JP2003503341A (ja) 2003-01-28
DK1194131T3 (da) 2005-01-17
NO20016282L (no) 2002-02-27
HUP0202259A2 (hu) 2002-12-28
US20080175910A1 (en) 2008-07-24
DE60013445D1 (de) 2004-10-07
KR100794402B1 (ko) 2008-01-16
HUP0202259A3 (en) 2004-05-28
EP1194131B1 (en) 2004-09-01
EP1194131A1 (en) 2002-04-10
SK19102001A3 (sk) 2002-05-09
IL146768A (en) 2010-05-17
ATE274902T1 (de) 2004-09-15
CA2370067A1 (en) 2001-01-04
HK1043056A1 (en) 2002-09-06
CZ20014639A3 (cs) 2002-04-17
PT1194131E (pt) 2005-01-31
WO2001000182A1 (en) 2001-01-04
CA2370067C (en) 2009-07-28
MXPA01013408A (es) 2002-07-30
SK285359B6 (sk) 2006-11-03
CN1358088A (zh) 2002-07-10
NZ515826A (en) 2004-04-30
DE60013445T2 (de) 2005-09-01
IL146768A0 (en) 2002-07-25
TR200103604T2 (tr) 2002-04-22
AU6274700A (en) 2001-01-31
AR024492A1 (es) 2002-10-02
EP1064938A1 (en) 2001-01-03
HU229312B1 (hu) 2013-10-28
CZ296067B6 (cs) 2006-01-11
ZA200109849B (en) 2003-02-26
NO332952B1 (no) 2013-02-11
SI1194131T1 (en) 2005-04-30
ES2225183T3 (es) 2005-03-16
AU780769B2 (en) 2005-04-14
CO5190681A1 (es) 2002-08-29
BR0011999A (pt) 2002-03-05
PL200816B1 (pl) 2009-02-27
HK1043056B (en) 2005-04-29
KR20020015065A (ko) 2002-02-27

Similar Documents

Publication Publication Date Title
HUP0202259A3 (en) Pharmaceutical dosage forms for controlled release producing at least a timed pulse
HUP0301242A3 (en) Controlled release drug dosage form
IL153282A0 (en) Method for preparing a pharmaceutical composition
IL148407A0 (en) Oral pharmaceutical forms of administration with a delayed action
EG24851A (en) Crystalline anticholinergic process for the preparation thereof for preparing a medicament
EG24142A (en) Crystalline monohydrate, process for the preparation thereof and the use thereof for preparing a pharmaceutical composition
HUP0101437A3 (en) Oral pharmaceutical extended release dosage form
EP1343481A4 (en) PROCESS FOR THE PREPARATION OF A QUICKLY SOLUBLE DOSAGE FORM
AU137637S (en) A pharmaceutical tablet
HUP0200669A3 (en) Process for producing pharmaceutical preparation for oral administration containing tolperison
IL146632A0 (en) Pharmaceutical tablets
AU137736S (en) A pharmaceutical tablet
EP1207852A4 (en) ORAL PHARMACEUTICALS WITH TAXED RELEASE FOR ORAL ADMINISTRATION
AU145547S (en) A tablet for example a pharmaceutical tablet
AU145546S (en) A tablet for example a pharmaceutical tablet
AP2004003087A0 (en) Oral dosage form for controlled drug release
AU1694501A (en) Method for producing a medicament
EP1114642A4 (en) MEDICAMENTS FOR THE TREATMENT OF PERIODONTAL DISEASES
AU2001282071A1 (en) Multiparticulate pharmaceutical dosage form and a method for producing the same
IL144767A0 (en) Method for producing film-type dosage forms
AU5092001A (en) Crystalline pharmaceutical
AU3547001A (en) Method for producing pharmaceutical dosage forms
GB0001481D0 (en) System for delivering a medicament
PL354872A1 (pl) Doustna postać dawki zawierająca sól morfiny lub pochodnej morfiny
IL128582A0 (en) Pharmaceutical dosage form